From Veep to President

From Veep to President

05.05.2015 - The Faculty of Pharmaceutical Medicine has reinforced its top ranks with the appointment of Professor Alan Boyd as its new President. Alan who is currently Vice President of the faculty, will take up office later this year on 19th November replacing Dr Keith Bragman who will have served a three-year term.

Alan is owner of Boyds consultancy business and began his pharmaceutical career 28 years ago at Glaxo Group Research Ltd. From 1988 he led ICI’s cardiovascular medical research team, later taking on the role of Director of Clinical and Medical Affairs at ICI Pharma in Canada. In 1999, after four years as Head of Medical Research for Zeneca Pharmaceuticals, he became Director of Research and Development for Ark Therapeutics Ltd where he was responsible for delivering the majority of key development milestones that have shaped the company. In April 2005, he left to set up Alan Boyd Consultants Ltd. The focus of the consultancy is to aid and support early stage life science based companies.

Alan is a graduate in Biochemistry and Medicine from the University of Birmingham. His experience will ensure that the Faculty will help further establish its role as a healthcare partner and in the outside world.

03.12.2014 Karus Therapeutics, a developer of medicines for the treatment of inflammatory diseases and cancer, has taken on two stars from the pharma world to strengthen its R&D team – Simon Roitt and Peter Finan.

Simon Roitt © Karus

Bringing 20 years of clinical development experience in the healthcare sector, Simon Roitt has been appointed as Head of Clinical Development at the UK company. With previous senior roles at Roche, GE Healthcare and Biocompatibles, Simon who joined Karus in August, will implement the company’s clinical development plans. As Karus’ newly appointed Head of Biology, Peter Finan has an extensive career in the pharma industry and has held a number of senior roles at Novartis over a period of 16 years. His last position at the pharma giant was VP, Global Head in respiratory disease. In his new role, Peter will work on Karus’ most advanced programme – a treatment for inflammatory disorders.

17.11.2014 French specialty vaccine developer Abivax has appointed Karl Birth­istle as Vice President Global Regulatory Affairs. At the same time, his colleague Daniel Kenny was named Chief Commercial Officer & VP of Business Development at the firm.


A physician by trade, Birthistle moved sideways into the pharma and biotech industries, where he has held positions focussing on drug, biologics and vaccines development, working at British SmithKlineBeecham, Dutch Pharming, Austrian Baxter Bio­Science and other firms. His most recent post was as Director of Clinical Development and Safety Assessments for Philip Morris in Switzerland. Birthistle remains Deputy Head of the Clinical Review Division of Swissmedic, the Swiss regulatory authority.

13.11.2014 Jamal Temsamani has been appointed as Director of Drug Development and Corporate at VECT-­HORUS, a Marseille-based biotechnology company that designs and develops peptide vectors facilitating the delivery of drugs or imaging agents.


Temsamani is also a member of the VECT-HORUS Management Committee. The molecular biologist most recently held the post of Vice President of R&D at French generic drug maker CLL Pharma and at Synt:em before it was acquired by CLL. He also worked at Hybridon’s Europe arm, where he was Scientific Director. Temsamani has published dozens of scientific articles, and is a co-inventor on 40 patents.

10.11.2014 German Alzheimer's specialist Probiodrug in November invited Inge Lues – who has acted as Chief Development Officer since 2013 – to join the board.

© Probiodrug

 Chairman of the Supervisory Board Erich Platzer said Lues had been instrumental in the company’s recent IPO on the Euronext Amsterdam. Before joining Probiodrug in 2008 as a research and development advisor, Lues was Head of Global Drug Discovery and Non-Clinical Development Pharma at Merck KGaA. Prior to that, she led Merck’s Business Area in Central Nervous Systems.

30.10.2014 Scottish specialist reagent manufacturer Link Technologies Ltd. has appointed David Ricketts as its new CEO. Ricketts has taken over the company’s lead from John Bremner in October.

© Link Technologies

Ricketts, a graduate of Oxford University, spent the last two years as CEO of stem cell specialist FibromEd. Before that, he was CEO of Belgian Pharma Diagnostics and also focused on business development for various smaller R&D companies.

27.10.2014 Sir Philip Hampton will join the Board of GlaxoSmithKline plc as Non-Executive Director next January. He will also take over the role of Chairman later that year. Hampton is currently Chairman of The Royal Bank of Scotland Group plc.

© Royal Bank of Scotland

Prior to that, he held the position of Chairman of J Sainsbury plc, and Group Finance Director at Lloyds TSB Group.  He is Senior Independent Director of Anglo American plc, Chairman of their Remuneration Committee and member of their Audit Committee. Hampton was knighted in the New Year Honours 2007.

24.10.2014 Former Co-Head of Global Healthcare Investment Banking at J.P. Morgan, Andrea Ponti, has taken over the role of non-executive director at Cell Medica, the London-based cellular therapeutics company.

© Cell Media

With an extensive network of contacts and over 25 years of experience in advising leading pharmaceutical and biotechnology companies across the globe, Andrea Ponti will play an important role in developing partnership and commercialisation opportunities for Cell Media's immunotherapy products. Before joining J.P. Morgan in 2008, Ponti was Partner, Managing Director and Head of European Healthcare, Consumer and Retail investment banking at Goldman Sachs. In 1996, he founded the European Healthcare Group.

17.10.2014 Jarrod Longcor the former Vice President of Corporate Development for Rib-X Pharmaceuticals has been appointed CBO at Avillion LLP.

© Avillion LLP

Jarrod Longcor brings over 18 years of pharmaceutical and biotech experience to the London-based drug development company. In his previous role at Rib-X Pharmaceuticals, Inc (now Melinta Therapeutics), Longcor was responsible for identifying and concluding several critical collaborations for the company. Prior to Rib-X, he held key positions in several small to mid-sized biotech companies where he was responsible for business development and strategic planning. At Avillion, Longcor will be responsible for structuring, negotiating and executing strategic alliances, co-development agreements, and financial instruments, as well as providing management and strategic leadership to the organisation.

16.10.2014 Biochemistry professor Michel Bouvier has been appointed as new chairman of the Scientific Advisory Board at Strasbourg-based Domain Therapeutics.

© Domain Therapeutics

As professor in the Department of Biochemistry and Molecular Medicine at the University of Montreal, and also CEO of the Institute for Research in Immunology and Cancer (IRIC), Michel Bouvier brings a wealth of experience and knowledge to the board at Domain Therapeutics. The biopharmaceutical company specialises in the research and development of new drug candidates targeting G protein-coupled receptors (GPCRs) and will assemble a team of experts in drug discovery and development. In the coming months, Bouvier will work closely with the Domain Therapeutics’ management team to assemble a group of academic and industrial peers.

08.10.2014 Karolinska Development has announced the appointment of its new CEO. Oncology expert Bruno Lucidi has been appointed CEO of the wholly owned subsidiary KDev Oncology and the portfolio companies Aprea and Akinion Pharmaceuticals.

© Karolinska Development

Lucidi has extensive international experience in the pharmaceutical industry. Before becoming CEO at Karolinska Development, Bruno previously held positions as CEO of Idenix and Chairman of Pharmasset, where he contributed to maturing the companies to a level that eventually resulted in both companies being acquired by multinational pharmaceutical companies. Lucidi has also held senior positions within Bristol-Myers Squibb and Global Head of Oncology Strategy, at Johnson & Johnson as Global Head of Oncology Strategy from Drug Discovery to Market and at GlaxoSmithKline.

Vorherige Seite4/25Nächste Seite


LentiKat’s offers an unusual investment opportunity

LentiKat’s owns, manufactures and distributes a patented immobilization into lentil-shaped Lentikats Biocatalysts. The unique lentil-like shape of the Lentikats Biocatalyst ensures unlimited diffusion of substrate(s) into any part of the matrix, while still retaining a convenient size for easy separation from the reaction medium. They find application in the Pharma & Food industry (including bio-based chemicals), Wastewater treatment as well as Biofuels. more...

Product of the week


Job Advert

Sales Manager

celares GmbH is a Berlin based drug delivery company focused on chemical modifications of biological drugs. We offer customized development services for international pharma and biopharma companies and have manufacturing capabilities for key starting materials used for the preparation of pharmaceutical drugs. For the intensification of our own sales activities we are looking for a sales manager. more...


All Events



BioVaria 2015

Stock list

All quotes


  • 4SC5.41 EUR4.04%
  • WILEX5.25 EUR3.35%
  • BIOFRONTERA2.34 EUR1.74%


  • VITA 345.86 EUR-6.69%
  • FORMYCON26.31 EUR-6.04%
  • MORPHOSYS63.42 EUR-6.02%


  • 4SC5.41 EUR322.7%
  • WILEX5.25 EUR83.6%
  • PAION2.85 EUR21.3%


  • BIOTEST72.00 EUR-25.9%
  • THERAMETRICS0.07 CHF-22.2%
  • MEDIGENE10.16 EUR-17.6%


  • SANTHERA96.00 CHF2361.5%
  • CYTOS1.27 CHF647.1%
  • WILEX5.25 EUR517.6%


  • MOLOGEN4.85 EUR-55.5%
  • THERAMETRICS0.07 CHF-30.0%
  • BIOFRONTERA2.34 EUR-26.6%

No liability assumed, Date: 05.05.2015

Current issue

All issues